INSM
What one share of Insmed holds
Pharmaceutical Preparations
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare.
Insmed’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.30 |
|---|---|
| Profit | −$4.08 |
| Capex (buildings and equipment) | $0.13 |
| Free cash flow | −$3.76 |
| Cash and investments | $5.32 |
| Debt | $2.59 |
| Book value | $3.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$2.85 | $0.07 | −$2.44 | — | $2.49 |
| 2017 | $0.00 | −$2.89 | $0.05 | −$2.44 | — | $4.71 |
| 2018 | $0.13 | −$4.22 | $0.17 | −$3.53 | — | $2.69 |
| 2019 | $1.61 | −$3.01 | $0.50 | −$3.46 | — | $2.92 |
| 2020 | $1.68 | −$3.01 | $0.06 | −$2.31 | — | $2.68 |
| 2021 | $1.68 | −$3.88 | $0.07 | −$3.31 | — | $3.46 |
| 2022 | $1.99 | −$3.91 | $0.08 | −$3.33 | — | $0.65 |
| 2023 | $2.17 | −$5.34 | $0.09 | −$3.91 | — | −$2.24 |
| 2024 | $2.22 | −$5.57 | $0.13 | −$4.30 | — | $1.59 |
| 2025 | $3.05 | −$6.42 | $0.16 | −$4.86 | — | $3.45 |